Bacteriophages as anti-infective agents: recent developments and regulatory challenges.
The biennial meeting on 'Exploiting Bacteriophages for Bioscience, Biotechnology and Medicine', held in London, UK, on 20 January 2012, and chaired by George Salmond (University of Cambridge, UK) hosted over 50 participants representing 13 countries. The highly multidisciplinary meeting covered a diverse range of topics, reflecting the current expansion of interest in this field, including the use of bacteriophages as the source of biochemical reagents for molecular biology, bacteriophages for the treatment of human and animal diseases, bacteriophage-based diagnostics and therapeutic delivery technologies and necessity for, and regulatory challenges associated with, robust clinical trials of phage-based therapeutics. This report focuses on a number of presentations from the meeting relating to cutting-edge research on bacteriophages as anti-infective agents.
School of Pharmacy, Queen's University of Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK. b.gilmore@qub.ac.uk
Brendan F
BF
Gilmore
D000279:Administration, Cutaneous; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D001419:Bacteria / Q000737:chemistry / Q000821:virology*; D001424:Bacterial Infections / Q000382:microbiology / Q000628:therapy; D001435:Bacteriophages / Q000737:chemistry / Q000254:growth & development / Q000472:pathogenicity*; D018441:Biofilms; D001691:Biological Therapy / Q000379:methods; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D004353:Drug Evaluation, Preclinical / Q000592:standards; D006801:Humans; D007880:Legislation, Drug; D014779:Virus Replication
D000890:Anti-Infective Agents